Listed

Celldex Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2016

Filed with the SEC on Mar 14, 2017 and accepted by EDGAR at Mar 14, 2017, 16:23 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-10-01 to 2016-12-31$1.9mus-gaap:Revenues
Research and development12 months2016-01-01 to 2016-12-31$102.7mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2016-01-01 to 2016-12-31−$132.9mus-gaap:OperatingIncomeLoss
Net income3 months2016-10-01 to 2016-12-31−$32.3mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income12 months2016-01-01 to 2016-12-31−$128.5mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2016-10-01 to 2016-12-31−$0.30us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS12 months2016-01-01 to 2016-12-31−$1.27us-gaap:EarningsPerShareBasicAndDiluted
Capital expenditure12 months2016-01-01 to 2016-12-31$2.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-12-31$42.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-12-31$195.6mus-gaap:AssetsCurrent
Total assetsAt period end2016-12-31$383.4mus-gaap:Assets
Current liabilitiesAt period end2016-12-31$35.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-12-31$117.9mus-gaap:Liabilities
Shareholders' equityAt period end2016-12-31$265.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001047469-17-001564. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.